Physician profile
Stephen D Keith
NPI 1609962117
$4,969.40
in general payments reported to CMS, 2019-2025
35 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,210 · 2020: $1,359 · 2021: $526 · 2022: $729 · 2023: $427 · 2024: $392 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038 · Gift: $97.20 · Education: $9.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,037.92 |
| Gift | $97.20 |
| Education | $9.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,393.22 | 2020-2025 | Da Vinci Surgical System |
| Boston Scientific Corporation | $890.46 | 2019 | |
| Novo Nordisk INC | $441.20 | 2019-2024 | Wegovy |
| Medtronic, INC. | $323.58 | 2022-2024 | Interstim |
| Astellas Pharma US INC | $317.10 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $257.25 | 2019-2023 | |
| Hologic Sales and Service, LLC | $207.70 | 2019-2025 | Novasure, Myosure Tissue Removal Device, Acessa Provu System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.52 | 2021 | |
| Organon LLC | $90.80 | 2024-2025 | Nexplanon, Jada System |
| Sumitomo Pharma America, INC. | $82.78 | 2023-2025 | Gemtesa |
| Laborie Medical Technologies Corp. | $72.35 | 2024-2025 | Eclipse |
| Bausch Health US, LLC | $64.45 | 2021-2022 | |
| Coopersurgical, INC. | $63.98 | 2024 | Summit Doppler, Wallach Cryosurgical Equipment |
| Mayne Pharma Commercial LLC | $57.81 | 2022-2023 | |
| Aspira Women'S Health INC | $53.91 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $49.31 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $45.85 | 2021-2022 | |
| Therapeuticsmd, INC. | $44.82 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.79 | 2023-2025 | |
| Urovant Sciences INC | $37.76 | 2022 | |
| Lupin INC. | $37.13 | 2020 | |
| Roche Diagnostics Corporation | $33.55 | 2019-2020 | |
| Pfizer INC. | $31.39 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $29.89 | 2020-2021 | |
| Virtus Pharmaceuticals LLC | $20.46 | 2021 | |
| Northgate Technologies, INC. | $20.26 | 2023 | Nti Branded Other (Nti) |
| Daiichi Sankyo INC. | $19.67 | 2021 | |
| Supernus Pharmaceuticals, INC. | $18.66 | 2025 | Qelbree |
| Monaghan Medical Corporation | $18.33 | 2023 | Aerobika |
| Becton, Dickinson and Company | $18.31 | 2019 | |
| Axonics, INC. | $16.55 | 2024 | Axonics |
| Evofem Biosciences, INC. | $13.68 | 2021 | |
| Scynexis, INC. | $13.54 | 2022 | |
| Lilly USA, LLC | $13.52 | 2023 | Zepbound |
| Avion Pharmaceuticals | $12.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Keith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.